| Print
Fortress Biotech (FBIO)
Common SharesThis share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Company profile
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq,Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.
Address
2 Gansevoort Street
9th Floor
New York
NY
USA
10014
Telephone
+1 781 652-4500
Forecast key dates
| Name | Key Date |
|---|---|
| Fortress Biotech Inc Third Quarter Earnings Results for 2026 | 2026-11-13T00:00:00 |
| Fortress Biotech Inc Annual General Meeting for 2026 | 2026-06-17T10:00:00 |
| Fortress Biotech Inc First Quarter Earnings Results for 2026 | 2026-05-15T00:00:00 |
| Fortress Biotech Inc First Quarter Earnings Conference Call for 2026 | 2026-05-14T16:30:00 |
| Fortress Biotech Inc Annual Report for 2025 | 2026-03-31T00:00:00 |
| Fortress Biotech Inc Fourth Quarter Earnings Results for 2025 | 2026-03-26T00:00:00 |
Previous key dates
| Name | Key Date |
|---|---|
| Fortress Biotech Inc Third Quarter Earnings Results for 2025 | 2025-11-14T00:00:00 |
| Lake Street Capital Markets 9th Annual Best Ideas Growth (BIG9) Conference | 2025-09-11T00:00:00 |
| H.C. Wainwright 27th Annual Global Investment Conference | 2025-09-08T13:30:00 |
| Fortress Biotech Inc Second Quarter Earnings Results for 2025 | 2025-08-14T00:00:00 |
| Fortress Biotech Inc Annual General Meeting for 2025 | 2025-06-17T10:00:00 |
| Fortress Biotech Inc First Quarter Earnings Results for 2025 | 2025-05-15T00:00:00 |
| Fortress Biotech Inc Annual Report for 2024 | 2025-03-31T00:00:00 |
| Fortress Biotech Inc Fourth Quarter Earnings Result for 2024 | 2025-03-26T00:00:00 |
| Commercial Launch Plan for Emrosi™ | 2025-02-05T16:30:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2026 AJ Bell. All rights reserved.